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Patients with Ischemic stroke are at high risk of having a new stroke or developing other vascular diseases such as 
acute myocardial infarction, or vascular death, known as vas-
cular recurrence. A study in the South London Stroke Register 
described a cumulative risk of vascular recurrence after a first 
stroke of 8.0% at 1 year and 16.6% at 5 years.1 To reduce vas-
cular recurrence, the most prescribed treatment for secondary 
prevention of stroke is antiplatelet agents,2 most widely used 
are acetylsalicylic acid, clopidogrel, or a combination of both. 
However 10% to 20% of patients treated with antiplatelet 
drugs have a new vascular event3; in addition, serious vascular 
events are reduced only by <25% compared with placebo.4
Pharmacogenetic studies have evaluated the relationship 
between genetic variants and high on-treatment platelet reac-
tivity usually assessing platelet aggregation.5 Mega et al5 
found an association between the CYP2C19 reduced-function 
allele and lower levels of the clopidogrel active metabolite, 
diminished platelet inhibition, and higher rates of major 
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adverse cardiovascular events. Shuldiner et al6 also found the 
CYP2C19*2 allele to be associated with diminished platelet 
response to clopidogrel treatment and poorer cardiovascular 
outcomes. Furthermore, Holmes et al7 found an association 
between the CYP2C19 genotype and clopidogrel responsive-
ness, although there was no significant association of geno-
type with cardiovascular events.
Pharmacogenetic studies have found single-nucleotide poly-
morphisms associated with platelet aggregation in clopidogrel-
treated patients; however, they have failed to find a genetic 
predisposition associated with new vascular events. Therefore 
new approaches, such as epigenetic studies, may contribute 
to finding the underlying cause of the occurrence of new vas-
cular events after clopidogrel treatment. Epigenetics refers to 
DNA modifications affecting gene expression and chromatin 
structure without altering the nucleotide sequence. Epigenetic 
modifications are stable, reversible, and heritable and can be 
modulated by many factors including physiological and path-
ological conditions and by the environment. Epigenetic pro-
cesses are involved in numerous cellular processes, and also 
related to some monogenic and complex human diseases.8
Recent studies have observed epigenetic mechanisms 
involved in the pathogenesis of atherosclerosis.9,10 Su et al11 
observed that lower P2Y12 gene promoter DNA methylation 
(DNAm) was associated with an increased risk of clopidogrel 
high on-treatment platelet reactivity in patients with albumin 
≤35 g/L, currently smoking, or abusing alcohol, suggesting 
a potential role for epigenetics in clopidogrel high on-treat-
ment platelet reactivity and vascular events after clopidogrel 
treatment.
The aim of this study is to analyze the whole epigenome 
of ischemic stroke patients treated with clopidogrel with an 
Epigenome-Wide Association Study (EWAS) to find altered 
methylation sites associated with new ischemic events (vascu-
lar recurrence) after first ischemic stroke.
Materials and Methods
Clinical Protocol
From a cohort of 1900 patients with stroke from Vall d’Hebron 
University Hospital (Barcelona, Spain), 42 subjects were selected. 
First, 21 subjects with ischemic stroke, who were treated with clopi-
dogrel after the first stroke and had a new vascular event (defined 
as new ischemic stroke, myocardial infarction, peripheral vascu-
lar disease, or cardiovascular death), were selected. The remaining 
21 subjects were selectively matched one-by-one with the first 21 
subjects (ischemic stroke patients treated with clopidogrel after the 
ischemic stroke event and without a new vascular event). Matching 
variables were age (±7 years), sex, Trial of Org 10172 in Acute Stroke 
Treatment (TOAST)12 classification, and clopidogrel administration 
(Table 1). Ethical committee approved the study (PR(AG) 03/2007). 
All patients were provided with oral and written information about 
the project, and signed the informed consent.
The study cases were defined as being patients with ischemic stroke 
who started clopidogrel treatment after stroke and who had a vascular 
recurrence in the first year of follow-up with a good adherence to the 
treatment as measured by the Morisky–Green test.13 Controls were 
defined as patients with ischemic stroke who started clopidogrel treat-
ment after stroke with a good adherence to the treatment but without 
vascular recurrence during the first year of follow-up. Vascular recur-
rence was described as new ischemic stroke, myocardial infarction, 
peripheral vascular disease, or cardiovascular death and was detected 
through telephone calls every 3 months or direct clinical visit.
Replication analysis was performed on 191 new samples from 
3 cohorts, 2 ischemic stroke patients’ cohorts and 1 cardiovascular 
disease patients’ cohort, for further information about sample selec-
tion and cohorts see Table I in the online-only Data Supplement. The 
replication cohort included 29 patients with cardiovascular disease 
(ischemic stroke and myocardial infarction) treated with clopidogrel 
with a new vascular event and 162 patients with cardiovascular dis-
ease treated with clopidogrel without a new vascular event during the 
first year of follow-up (Table 1).
DNA Preparation and Bisulfite Conversion
Total genomic DNA was extracted from whole blood samples 
obtained during the first 24 hours after stroke onset before clopidogrel 
initial administration using the Gentra Puregene Blood Kid (Quiagen, 
Hilden, Germany) following the manufacturer’s instructions.
Infinium HumanMethylation450 
BeadChip Discovery Assay
Genome-wide DNAm was assessed using the Infinium 
HumanMethylation450 BeadChip (Illumina Inc, San Diego, CA). All 
samples were processed in a single working batch.
All preprocessing, correction, normalization steps, and plots 
were implemented using the R statistical computing environment 
(3.1.3 version) with Bioconductor packages (Table II in the online-
only Data Supplement). Quality control metrics were examined to 
determine the success of the bisulfite conversion and subsequent 
array hybridization. Fluorescence intensities were imported from 
GenomeStudio, then probe filtering was performed to remove 
probes that have failed to hybridize (detection P>0.05) and that are 
not represented by a minimum of 3 beads on the array, as described 
elsewere.14,15 CpG sites containing documented single-nucleotide 
polymorphisms were also excluded.16 Multidimensional scaling 
plots were used to evaluate sex outliers based on chromosome X 
data. Multidimensional scaling and principal components were also 
used to check unknown population structures. Probes mapping to sex 
chromosomes were removed. We also checked the white cell count 
(neutrophils, lymphocytes, and monocytes) as a possible confound-
ing factor. Finally, a subset quantile normalization was performed 
using a background adjustment between-array normalization and a 
dye bias correction, following previous recommendations.15
The methylation level of each cytosine was expressed as a β-value, 
which ranged between 0 and 1, unmethylated to completely meth-
ylated, respectively. Differentially methylated CpG (DMCs) sites 
were analyzed using the nonparametric Mann–Whitney U test for 
independent samples, P values<10−06 were selected as statistically 
significant17 and P values<10−05 as nominal association. Multivariable 
generalized linear analyses adjusting for Principal Components and 
DNAm potential covariates (age, sex, and current smoking) were also 
used.
MassARRAY EpiTYPER, Replication Assay
Quantitative DNAm analysis was performed using the MassARRAY 
EpiTYPER (Sequenom, San Diego, CA) on 3 selected CpGs from the 
450-k array discovery study. Selection criteria: have at least a nom-
inal association with vascular recurrence (P<10−05), be in a region 
suitable for MassARRAY EpiTYPER analysis (not all CpGs could 
be analyzed), and map on a gene previously related to inflammatory 
processes or cardiovascular events in the literature (bibliographic 
research performed in PubMed [http://www.ncbi.nlm.nih.gov/
pubmed], using the keywords clopidogrel, atherosclerosis, ischemic 
and vascular). Target-specific primers were designed using the online 
software Epidesigner [http://www.epidesigner.com], list of primers 
in the Table III in the online-only Data Supplement). The quantita-
tive methylation data obtained for each CpG site, or aggregates of 
multiple CpG sites, were analyzed with the EpiTYPER software 
(Sequenom). Statistical analyses were performed using R (3.1.3 ver-
sion). P values <0.05 were considered as statistically significant, after 
the Mann–Whitney U test.
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CYP2C19*2 Analysis
We checked the CYP2C19*2 polymorphism (rs4244285) that has 
been strongly associated with clopidogrel responsivenes6,7 to know 
whether it could be a confounding factor in the EWAS analysis (com-
plete Methods in the online-only Data Supplement).
Platelet Aggregation Assay
Spearman rank correlation was used to estimate the correlation between 
methylation levels of replicated CpGs and platelet aggregation. Values 
from a subgroup of 90 subjects from the replication study were used. 
Platelet aggregation values were obtained using Light Transmission 
Aggregometry with ADP as the agonist at a concentration of 5 μmol/L.18
TRAF3 in Aspirin-Treated Patients
A group of patients with stroke treated only with aspirin (n=38) were 
selected from the Vall d’Hebron University Hospital’s cohort follow-
ing the same inclusion and exclusion criteria used for clopidogrel-
treated patients. Of these, 19 patients presented a new vascular event 
during the first year of follow-up and 19 patients, matched for age, 
sex, and TOAST, did not present a vascular recurrence. Methylation 
levels of 37 CpGs located in tumor necrosis factor receptor–associ-
ated factor 3 (TRAF3) gene were analyzed in this group. See online-
only Data Supplement.
Statistical Analysis
A sample size of 21 subjects per condition was needed to achieve 
a 10−05 significance level and 80% statistical power, considering a 
Cohen effect size=1.8. Sample size calculation was performed using 
the pwr package (version: 1.1–2) from Bioconductor (http://www.
bioconductor.org).
Continuous variables were compared using the Mann–Whitney U 
test, multivariable generalized linear analysis, or Spearman correla-
tion test for nonparametric samples, using the R software (http://www.
cran.r-project.org).
Results
Epigenome-Wide Analysis
Epigenome-wide analysis of the 485 577 CpG sites was 
assessed using the Illumina 450-k BeadChip across the whole 
genome in each of the 42 individual samples. After prepro-
cessing and QC analysis, 34 059 CpG sites and 1 sample were 
removed from further analysis: 1848 CpGs with detection P 
>0.05, 20 935 CpGs that overlap with single-nucleotide poly-
morphisms, and 11 276 CpGs located on sexual chromosomes, 
and 1 sample with sex discrepancies.
Table 1. Descriptive Characteristics of the Study Population
Vascular 
Recurrence
Nonvascular 
Recurrence
Vascular 
Recurrence
Nonvascular 
Recurrence
Discovery cohort (n=42) Replication cohort (n=191)
n 21 (50%) 21 (50%) 29 (15%) 162 (85%)
Age, y 70.25±8.7 71.68±8.3 69±10 66±10
Male 18 (85.7%) 18 (85.7%) 16 (55.2%) 140 (86.8%)
Female 3 (14.3%) 3 (14.3%) 13 (44.9%) 42 (26%)
TOAST
  Aterothrombotic 11 (52.4%) 11 (52.4.2%) 3 (10.4%) 21 (13%)
  Lacunar 5 (23.8%) 5 (23.8%) 1 (3.5%) 10 (6.2%)
  Undetermined 4 (19%) 4 (19%) 3 (10.4%) 35 (21.7%)
  Other 1 (4.8%) 1 (4.8%) 13 (44.9%) 12 (7.4%)
Presence of dyslipidemia 12 (57.1%) 8 (38.1%) 5 (17.3%) 52 (32.2%)
Presence of diabetes mellitus 8 (38.1%) 8 (38.1%) 6 (20.4%) 33 (20.5%)
Presence of hypertension 13 (29.9%) 17 (39.1%) 22 (75.9%) 102 (63.2%)
Current smoker 15 (71.4%) 18 (85.7%) 3 (10.4%) 23 (14.3%)
Alcohol 11 (52.4%) 19 (90.4%) … …
Previous myocardial infarction 2 (9.5%) 1 (4.76%) 4 (13.8%) 98 (60.8%)
Previous coronary intervention … … 5 (17.3%) 28 (17.4%)
Previous angina 2 (9.5%) … 2 (6.9%) 8 (5%)
Previous tumor 2 (9.5%) 1 (4.76%) 5 (17.3%) 5 (3.1%)
Statin 11 (52.4%) 14 (66.6%) 13 (44.9%) 88 (54.6%)
  Atrovastatine 8 (38.1%) 7 (33.3%) 3 (10.4%) 35 (21.7%)
  Provastatine … … 1 (3.45%) 17 (10.5%)
  Rosuvastatine … … … 13 (8.1%)
  Sinvastatine 3 (14.3%) 4 (19%) 4 (2.1%) 8 (5%)
  Unknown … 3 (14.3%) 5 (17.3%) 13 (8.1%)
Discovery cohort n=42, replication cohort n=191. TOAST indicates Trial of Org 10172 in Acute Stroke Treatment.
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The methylation intensities showed bimodal distribution 
when displayed across all probes (Figure IA in the online-
only Data Supplement), but approximately normal distribu-
tion for most CpGs when they were considered individually 
(Figure IB in the online-only Data Supplement). The −log10 
(P value) values from DMCs site analysis were plotted for 
451 518 CpGs across the genome (Figure 1). Seventy-three 
candidate DMCs were associated with vascular recurrence in 
stroke patients treated with clopidogrel with nominal associa-
tions P values (P<10−05; Table 2).17 Figure 2 shows a hierarchi-
cal cluster analysis for a panel of the top 73 significant DMC 
sites (P<10−05), this is able to distinguish vascular recurrence 
patients from nonvascular patients (with only 1 sample mis-
classified). A heatmap of the 73 DMCs is shown in the Figure 
II in the online-only Data Supplement. Among the 73 DMCs, 
48 had higher and 25 had lower DNAm levels in patients with 
a recurrent vascular event compared with patients with non-
recurrence (Figure III in the online-only Data Supplement).
Replication Analysis
The replication analysis of 3 CpG sites was performed for 191 
new samples by MassARRAY EpiTyper. The selected CpGs 
mapped to 3 genes known to be involved in atherosclerosis and 
vascular processes and could be analyzed by MassARRAY 
Figure 1. Epigenome-wide association between vascular recurrence patients and nonvascular recurrence patients of 451 518 CpGs. Sev-
enty-three CpGs reached statistical significance, trend (P<10–5), represented by the horizontal line. x-axis indicates chromosome position, 
and y-axis indicates −log10 of P values for each CpG site.
Table 2. Differentially Methylated CpG (DMC) Sites Associated With Vascular 
Recurrence in Patients With Stroke Treated With Clopidogrel
CpG ID Chr Position Gene Mapping to Gene P Value
cg06726262 17 15602873 ZNF286A TSS200 1.29E-06
cg09332091 19 3180708 4.18E-06
cg09533145 5* 178563145* ADAMTS2* Body* 7.81E-06*
cg18002896 8 144465845 RHPN1 3’UTR 7.81E-06
cg07925064 16 90114301 LOC100130015 TSS200; TSS1500 1.06E-05
cg14630099 6 32975702 HLA-DOA Body 1.06E-05
cg01348374 3 181313591 1.23E-05
ch,18,400468R 18 20395250 1.23E-05
cg03548645 14* 103369816 TRAF3* Body* 1.42E-05*
cg10318528 4 154702461 SFRP2 3’UTR 1.89E-05
cg15107336 19* 44079778* XRCC1* TSS200* 1.89E-05*
cg27093242 3 32927448 TRIM71 Body 1.89E-05
cg16126516 19 46850186 PPP5C TSS200 2.51E-05
cg18997433 4 24585879 DHX15 Body 2.51E-05
cg22849543 20 46997755 LOC284749 Body 2.51E-05
Top 15 most significant CpGs (P<10–5), see Table V in the online-only Data Supplement for full 73 DMCs.
*Selected CpGs for replications.
 at UniversitÃƒÂ  degli Studi di Brescia on June 13, 2016http://stroke.ahajournals.org/Downloaded from 
1184  Stroke  May 2016
EpiTyper (ADAMTS2 cg09533145, P=7.81×10−06; XRCC1 
cg15107336, P=1.89×10−05; and TRAF3 cg03548645, 
P=1.42×10−05). Three 400-pb regions containing each one of 
the 3 selected CpG sites, including other CpG sites and aggre-
gates, were sequenced. For all analyzed regions, the averaged 
directions of methylation changes were consistent with the 
methylation changes observed in the 450-k BeadChip array.
The CpG site mapped to TRAF3 gene cg03548645 was asso-
ciated with vascular recurrence (P=0.034), in the replication 
cohort. In addition, 3 new aggregated CpGs were associated 
with vascular recurrence de novo (Table 3). The cg03548645 
CpG site was independently analyzed for each individual 
cohort from the validation stage (Spanish, P=0.83; Italian, 
P=0.2; and Swiss, P=0.15) and showed the same methyla-
tion pattern in each one of them (Figure IV in the online-only 
Data Supplement). Lower methylation levels were associated 
with vascular recurrence. These results were consistent with 
the ones observed when we analyzed the 3 cohorts together, 
which reaches statistical significance because of the increased 
statistical power as a result of the larger sample size.
Cardiovascular risk factors (age, sex, and current smok-
ing) were analyzed as possible confounding factors in the 
discovery cohort, TRAF3 was independently associated 
with vascular recurrence (P=1.33×10−3). In addition, TRAF3 
methylation levels were not influenced by cell-type propor-
tions. When excluding patients with previous tumors, as pos-
sible confounding factor because of an increased activation 
of the inflammation pathway, TRAF3 was still associated 
with vascular recurrence (P<3.33×10−05). The frequency dis-
tribution of the CYP2C19*2 (rs4244285) polymorphism, 
previously associated with clopidogrel responsiveness,6,7 was 
also checked. The risk allele was equally distributed between 
patients (n=5) and controls (n=5), P=0.87. We also checked 
the methylated status of 5 CpGs of CYP2C19 gene, none of 
them presented statistically significant results (Table IV in the 
online-only Data Supplement).
In addition, an inverse statistically significant correla-
tion (ρ=−0.29, P=0.0075) was observed between DNAm 
levels (cg03548645 and TRAF3) and platelet aggregation 
(Figure 3), indicating that TRAF3 methylation was associ-
ated with a biochemical resistance to clopidogrel activity. 
Moreover, we observed that the methylation differences in 
cg03548645 were not stroke subtype dependent because we 
observed the same differences between recurrent and non-
recurrent stroke patients within the group of atherothrom-
botic strokes (P=0.011), and between the group of patients 
with nonatherothrombotic stroke (P=0.007; Figure V in the 
online-only Data Supplement). When the 37 CpG sites of 
TRAF3 were assessed in aspirin-treated patients, no asso-
ciation was found between cg03548645 and vascular recur-
rence (P=0.48). However, TRAF3 cg03548645 methylation 
was lower in patients with vascular recurrence. Importantly, 
a different CpG site was associated with vascular recurrence 
(cg14008679, P=5.41×10−4). Patients treated with aspirin 
showed the same methylation pattern that clopidogrel-treated 
patients for these 2 CpG sites, with lower TRAF3 methylation 
levels associated with vascular recurrence (Figure VI in the 
online-only Data Supplement).
Discussion
We performed the first genome-wide DNAm profiling of vas-
cular recurrence in clopidogrel-treated patients with stroke. 
High-throughput DNAm array-based profiling covering 
>450 000 CpG sites of the human genome was complemented 
by MassArray replication of the most physiopathologically 
relevant results. Quantitative DNAm identified DMCs sites 
mapped to atherosclerosis and vascular process–related genes.
The EWAS revealed 73 DMCs associated with vascu-
lar recurrence in clopidogrel-treated stroke patients. After 
EpiTYPET analysis, the association with the cg03548645, 
Figure 2. Hierarchical cluster analysis of most significant DMC associated with vascular recurrence in clopidogrel patients. Notice the 
nearly perfect segregation between the vascular recurrence samples (CA) and the nonvascular recurrence samples (CO).
Table 3. Differentially Methylated CpG Sites Identified De 
Novo, and the One Replicated in the MassARRAY Replication 
Study
CpG ID Identification Chr Gene P Value
TRAF3_1,2 Replicated 14 TRAF3 0.03441
TRAF3_6,7,8 De novo 14 TRAF3 0.04089
XRCC1_19,20 De novo 19 XRCC1 0.04195
XRCC1_36 De novo 19 XRCC1 0.04261
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mapping to TRAF3, was replicated. The results of the valida-
tion stage were not affected by the heterogeneity of the sam-
ple. There were no differences between patients with ischemic 
stroke and patients with cardiovascular disease. Furthermore, 
the methylation pattern of the TRAF3 was similar in the 3 
cohorts tested, being consistently lower in the patients with 
vascular recurrence. The combined analysis of the 3 cohorts 
reached sufficient statistical power to detect significant 
associations.
As further support of our findings, cg03548645 platelet 
aggregation levels were correlated with the DNAm levels. The 
differences between cases and controls were independent of 
stroke subtype. Furthermore, the CYP2C19*2 polymorphism 
was not a confounding factor because it was equally distrib-
uted between our groups (P=0.872). Furthermore, CYP2C19 
was not differentially methylated between recurrent and non-
recurrent patients.
The TRAF3 encodes a protein member of the TRAF family. 
These proteins participate in the signal transduction of CD40 
and tumor necrosis factor receptor, important to immune 
response activation. It has been shown that patients having 
cardiovascular disease exhibit increased levels of circulating 
and soluble CD40 ligand (DC40L).19,20 Song et al21 described 
association between TRAF3 gene expression and CD40 levels 
in arterial injury, also Pluvinet et al22 highlight the anti-inflam-
matory potential of RNAi-mediated CD40 inhibition, and the 
relevance of CD40 signaling for therapeutic intervention. del 
Río-Espínola et al23 also found an association between CD40 
polymorphisms and reocclusion risk after fibrinolysis during 
the acute phase of ischemic stroke.
Zirlik et al24 investigated TRAF expression in murine and 
human atherosclerotic plaques. They found increased expres-
sion levels of TRAF2 and TRAF3 protein in atherosclerotic 
tissues compared with nondiseased tissue. The results also 
establish the functional relevance of these TRAF families 
for proinflammatory signaling events in endothelial cells, 
and hence in inflammatory vascular diseases such as athero-
sclerosis. A recent study has also found TRAF3 upregulation 
associated with hypertrophied mice hearts and failing human 
hearts. Transgenic mice overexpressing TRAF3 in the heart 
developed exaggerated cardiac hypertrophy.25
Our results indicate significantly lower DNAm levels of 
CpG cg03548645 in patients who had vascular recurrence 
during clopidogrel treatment, compared with those who did 
not have vascular recurrence during the first year of follow-
up. These results were not influenced by common cardio-
vascular risk factors (P=1.33×10−03) or previous presence of 
tumors (P=3.33×10−05). A replication study was conducted 
on randomly selected samples from 3 international cohorts. 
cg03548645 remained significantly associated (P=0.034) and 
a new CpG aggregate, located ≈150-bp downstream from 
the main site, was also significantly associated with vascu-
lar recurrence (P=0.040). All results were consistent in the 
discovery and the replication study; in both studies, recur-
rent patients show lower methylation levels than nonrecurrent 
patients. When cg03548645 DNAm levels were analyzed on 
aspirin-treated patients, no association with vascular recur-
rence was found. However, lower cg03548645 methylation 
levels were observed in vascular recurrent patients, this trend 
was the same observed in clopidogrel-treated patients. In 
addition, a second TRAF3 CpG site (cg14008679) was found 
associated with vascular recurrence during aspirin treatment, 
with recurrent patients showing lower methylation levels in 
comparison wth nonrecurrent patients. We hypothesize that 
TRAF3 lower methylation may be directly related to vascu-
lar recurrence regardless aspirin or clopidogrel administra-
tion. However, the sample size for aspirin-treated patients is 
too small to validate this hypothesis. This hypothesis should 
be further investigated in future studies with patients on other 
antiplatelet or anticoagulants drugs.
The cg03548645 CpG is located in the TRAF3 gene body. 
Lower DNAm levels in gene bodies have been associated with 
higher levels of gene expression.26 Therefore, we hypothesize 
that TRAF3 expression may be higher in the vascular recurrence 
patients, which might increase the CD40 ligand signal transduc-
tion, thereby enhancing platelet–platelet interactions, secretion, 
and thrombus growth under artherogenic conditions.27
In addition to the association with vascular recurrence in 
on-clopidogrel treatment patients, we also found that lower 
cg03548645 DNAm levels were correlated with higher platelet 
aggregation (ADP-induced platelet aggregation; P=0.0075). 
This association indicates that epigenetics might be involved 
in the vascular recurrence of stroke and in the pharmacody-
namics of clopidogrel. Further studies will be needed to dis-
cern if the TRAF3 (cg03548645) association with vascular 
recurrence in stroke is because of an increased risk of ath-
erosclerosis, to the inhibition of clopidogrel activity or to a 
combination of both processes.
The next steps will include the analyses of TRAF3 transcrip-
tional levels in patients treated with clopidogrel and, it could 
also be interesting to study these findings in animal models to 
determine the role of TRAF3 and the reason of the association 
Figure 3. Correlation between cg03548645 DNAm values and 
platelet aggregation (ρ=−0.29, P=0.0075). x-axis indicates 
β-values for CpG 1.2 from EpiTYPER analysis, and y-axis indi-
cates ADP 5 µmol/L aggregation percentage by light transmission 
aggregometry (LTA).
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with vascular recurrence. Prospective studies analyzing the 
methylation levels previous to secondary prevention treatment 
and post recurrence will also be helpful to determine whether 
TRAF3 methylation levels can act as a predictive tool in the 
clinical practice. In summary, the measurement of methyla-
tion levels could be, in the future, useful to predict a higher 
risk of recurrent stroke in patients treated with clopidogrel and 
to pave the way for an improved personalized management.
Limitations
Analysis of mRNA expression levels was not possible in our 
study cohorts. Further analysis are needed to confirm the bio-
logical meaning of the results. Sample size of discovery phase 
(clopidogrel and aspirin) was relatively small, although the 
study had enough statistical power to reach epigenome-wide 
significance.
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Supplemental Data 
Supplemental methods. 
CYP2C19*2 analysis:  
 OmniQuadHuman 1M (Illumina). was used to genotype the samples. Data was 
analyzed following WTCC recommendation and the specific methodological guidelines 
from the Broad Institute and Harvard University. Quality controls (QC) were perform 
before the analyses.: Missings (-0.3) and checksex QCs were perform for each individual. 
Only individuals with Caucasian ethnicity were included. We also tested for population 
stratifications by analyzing the individual IBS, performing MDS plots and adjusting for 
principal components (PCs). Hardy-Weinberg (p-value>10-08), missingness (0.01), Mishap 
(p-value>10-09), were analyzed for each SNP.  
 After QC process, the genotypic results were analyzed by Plink, Haploview, 
STATA, SNPtest and GTOOL software solutions.  
Replication cohorts 
 The Italian and Spanish cohorts consist of consecutively recruited patients that 
started clopidogrel treatment after the first ischemic stroke. Vascular recurrence 
information was available from all patients. 
 The Geneva cohort consists of consecutively recruited patients with symptomatic 
documented ischemic atherothrombotic disease (coronary artery disease [CAD], ischemic 
cerebrovascular disease and/or peripheral artery disease) treated with aspirin and/or 
clopidogrel for < 5 years. Information about clinical ischemic events over an ongoing 3-
years follow-up was available from all patients. Only clopidogrel treated patients were 
selected from this cohort.  
 All samples with enough DNA concentration for Sequenom EpiTYPER analysis 
available, were selected from each cohort (Supplemental Table I). 
TRAF3 in aspirin treated patients assay: 
 Thirty eight subjects from a cohort of 1.900 ischemic stroke patients recruited 
prospectively at Vall d'Hebron Hospital (Barcelona, Spain), who started aspirin treatment 
after the first ischemic stroke were analyzed. Nineteen participants presented a new 
vascular event during the first year of follow up, and were matched one-to-one with 19 
participants without a new vascular event. Ethical approval was obtained from the ethical 
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committee of the Vall d’Hebron Hospital (PR(AG) 03/2007). Each participant signed the 
informed consent for the study. 
 Total genomic DNA was extracted from whole blood samples using Gentra 
Puregen Blood Kid (Quiagen, Hilden, Germany) following the manufacturer's instructions. 
Samples were obtained during the first 24h after stroke onset, before aspirin initial 
administration. Quality control (QC) of all samples was performed to check the DNA 
integrity before bisulfite conversion. 
 Genome-wide DNA methylation was assessed using the Infinium 
HumanMethylation450 BeadChip (Illumina Inc., San Diego Ca) that analyze methylation 
levels of 485.577 CpGs sites. All samples were processed in a single working batch. All 
pre-processing, correction and normalization steps as well as plots, were implemented 
using the computing environment R (3.1.3 version) with Bioconductor packages. QC and 
pre-processing steps were the same as described in the main manuscript for the 
clopidogrel analysis. Differentially methylated CpG sites (DMC) between vascular 
recurrent patients and non vascular recurrent patients were analyzed using the non 
parametric Mann-Whitney U-test for independent samples, only in 37 CpG sites located in 
the TRAF3 genes. 
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Supplemental Table I: Descriptive characteristics of the 3 replication cohorts. 
 
Switzerland's Cohort Italy's Cohort Spain's Cohort 
 
Rec Non-Rec Rec Non-Rec Rec Non-Rec 
N 8 (8.9%) 82 (91%) 17 (19%) 72 (80.6%) 4 (33.4%) 8 (66.6%) 
Age (years) 68±10 71±11 70±12 68±14 69±7 65±8 
Male 6 (75%) 69 (84.2%) 7 (41.2%) 45 (62.1%) 3 (75%) 6 (75%) 
Female 2 (25%) 13 (15.9%) 10 (58.8%) 27 (37.3%) 1 (25%) 2 (25%) 
Presence  
Dyslipidemia 
4 (50%) 50 (61%) - - 1 (25%) 2 (25%) 
Presence 
Diabetes Mellitus 
2 (25%) 20 (%) 3 (17.6%) 9 (12.4%) 0 4 (50%) 
Presence 
Hypertension 
7 (87.5%) 54 (24.4%) 11 (64.7%) 44 (60.72%) 4 (100%) 4 (50%) 
Current Smoker 1 (12.5%) 22 (26.8%) 2 (11.8%) - 0 1 (12.5%) 
TOAST 
      
Atherothrombotic 
  
3 (17.6%) 18 (24.4%) 0 3 (37.5%) 
Lacunar 
  
1 (5.9%) 8 (11%) 0 2 (50%) 
Undetermined 
  
1 (5.9%) 35 (48.3%) 3 (75%) 0 
Other 
  
12 (70.6%) 11 (15.2%) 1 (25%) 1 (12.5%) 
Previous Myocardial 
Infarction 
1 (12.5%) 23 (28.1%) 3 (17.6%) 25 34.7(%) - - 
Previous Coronary 
Intervention 
4 (50%) 28 (34.2%) - - 1 (25%) - 
Previous Angina - 8 (9.8%) 1 (5.9%) - 1 (25%) - 
Previous Tumor - - 4 (23.52%) 5 (6.9%) 1 (25%) - 
Statin 6 (75%) 71 (86.6%) 3 (17.6%) 11 (15.2%) 4 (100%) 6 (75%) 
Atrovastatine 3 (37.5%) 35 (42.7%) - - - - 
Provastatine 1 (12.5%) 17 (20.7%) - - - - 
Rosuvastatine - 13 (15.9%) - - - - 
Sinvastatine 2 (25%) 8 (9.8%) - - 2 (50%) - 
Unknown - 2 (2.4%) 3 (17.6%) 11 (15.2%) 2 (50%) - 
 
Supplemental Table II: Bioconductor packages for the processing and analysis of array-
based DNAm data. 
DNAm processing/analysis step Bioconductor packages 
Methylation data loading MethyLumi 
Quality control sample/probe wateRmelon, minfi 
Normalization and background correction wateRmelon 
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Supplemental Table III: Sequences of primers used in MassARRAY EpiTYPER 
replication study. 
Gene Primer* Size Sequence 
Product 
Size 
Nº of 
CpGs 
Coverage 
TRAF3 
LP 25 GGGTTAGTAGTGTGTATTTGGGTTT 
327 12 9 
RP 25 ACCAACAAATCCTAACCTCTACCAT 
XRCC1 
LP 25 GTTTGGTTAGAAGGATGAGGTAGAG 
476 37 26 
RP 25 TCCATCCTAAATAAAAAAACAAAACC 
ADAMTS2 
LP 25 GGAGTTTTGATGGTTTTTTTATGTG 
408 13 11 
RP 25 CCTCAACCTCCCAAATATCTAAAAT 
* LP, Left Primer; RP, Right Primer. 
 
Supplemental Table IV: Differentially methylated analysis of the 5 CpG sites located in 
CYP2C19 gene, present in the Illumina BeadChip array.  
CpG ID Chr Position Gene p-value 
cg00051662 10 96521086 CYP2C19 0,672 
cg04189838 10 96523347 CYP2C19 0,901 
cg18564458 10 96522433 CYP2C19 0,901 
cg20031717 10 96523248 CYP2C19 0,126 
cg24857560 10 96521152 CYP2C19 0,369 
 
Supplemental Table V: Top 73 differentially methilated CpG sites (p-value<10-5), 
associated with vascular recurrence in stroke patients treated with clopidogrel. 
CpG ID Chr Position Gene Mapping to gene p-value 
cg06726262 17 15602873 ZNF286A TSS200 1,29E-06 
cg09332091 19 3180708 
 
 
4,18E-06 
cg09533145 5 178563145 ADAMTS2 Body 7,81E-06 
cg18002896 8 144465845 RHPN1 3'UTR 7,81E-06 
cg07925064 16 90114301 LOC100130015 TSS200; TSS1500 1,06E-05 
cg14630099 6 32975702 HLA-DOA Body 1,06E-05 
cg01348374 3 181313591 
 
 
1,23E-05 
ch,18,400468R 18 20395250 
 
 
1,23E-05 
cg03548645 14 103369816 TRAF3 Body 1,42E-05 
cg10318528 4 154702461 SFRP2 3'UTR 1,89E-05 
cg15107336 19 44079778 XRCC1 TSS200 1,89E-05 
cg27093242 3 32927448 TRIM71 Body 1,89E-05 
cg16126516 19 46850186 PPP5C TSS200 2,51E-05 
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cg18997433 4 24585879 DHX15 Body 2,51E-05 
cg22849543 20 46997755 LOC284749 Body 2,51E-05 
cg00660096 17 81023323 
 
 
2,88E-05 
cg06419964 17 34965294 MRM1 3'UTR 2,88E-05 
cg18769818 11 72433059 ARAP1 
5'UTR; 1stExon; 
Body 
2,88E-05 
cg03654504 1 37495105 GRIK3 Body 3,31E-05 
cg14258853 12 29935411 TMTC1 5'UTR 3,31E-05 
cg27553667 15 27216083 GABRG3 TSS1500 3,31E-05 
cg05036153 9 140128254 SLC34A3 Body 3,79E-05 
cg12096506 11 134341284 
 
 
3,79E-05 
cg16149238 2 23608001 KLHL29 TSS1500 3,79E-05 
cg11841562 5 128320387 SLC27A6 Body 4,33E-05 
cg14793406 12 115135906 
 
 
4,33E-05 
cg17761538 8 145753477 
MGC70857; 
LRRC24 
Body; TSS1500 4,33E-05 
cg20908919 12 42877995 PRICKLE1 
5'UTR; TSS200;  
TSS1500 
4,33E-05 
cg25146814 17 78977970 
 
 
4,33E-05 
cg07480754 16 88298508 
 
 
4,94E-05 
cg09131511 2 163089214 FAP Body 4,94E-05 
cg12624825 9 94895189 LOC100128076 Body 4,94E-05 
cg21285198 1 1360970 TMEM88B TSS1500 4,94E-05 
cg24997845 2 191878460 STAT1 5'UTR 4,94E-05 
cg26243551 6 99873348 SFRS18 TSS200 4,94E-05 
cg00169917 10 120514287 C10orf46 1stExon; 5'UTR 5,64E-05 
cg00571292 8 74792031 UBE2W TSS1500 5,64E-05 
cg03331123 5 67511540 
 
 
5,64E-05 
cg11539992 17 74497631 RHBDF2 TSS200 5,64E-05 
cg25236894 17 5323110 RPAIN; NUP88 
Body; 1stExon; 
5'UTR; TSS200 
5,64E-05 
cg27073311 6 155091036 RBM16 Body 5,64E-05 
cg03523799 13 98913531 FARP1 Body 6,42E-05 
cg05141341 7 44796036 ZMIZ2 Body 6,42E-05 
cg09156140 5 43515218 C5orf34 TSS200 6,42E-05 
cg16575530 2 8118404 LOC339788 TSS1500 6,42E-05 
cg17737641 12 71834466 LGR5 Body 6,42E-05 
cg24951140 8 29156846 
 
 
6,42E-05 
cg00048178 6 13488257 GFOD1 TSS1500 7,30E-05 
cg10609205 3 112770222 
 
 
7,30E-05 
cg12389025 6 30028738 ZNRD1; TSS1500; Body 7,30E-05 
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NCRNA00171 
cg13826709 21 46708041 
POFUT2; 
LOC642852 
TSS1500; Body 7,30E-05 
cg26322913 14 50999702 MAP4K5; ATL1 TSS1500; TSS200 7,30E-05 
cg26326806 3 186153174 
 
 
7,30E-05 
cg01973920 5 980997 
 
 
8,28E-05 
cg07669969 5 60608527 
 
 
8,28E-05 
cg12181407 5 54052513 
 
 
8,28E-05 
cg14487854 17 714866 NXN Body 8,28E-05 
cg15208267 4 119760467 
 
 
8,28E-05 
cg24087403 10 71078535 HK1 Body; TSS200 8,28E-05 
cg24532669 11 66112147 BRMS1 5'UTR 8,28E-05 
cg25629418 12 1929265 
LRTM2; 
CACNA2D4 
TSS200; Body 8,28E-05 
cg26529771 16 89260650 CDH15 Body 8,28E-05 
cg27513517 1 183439365 
 
 
8,28E-05 
cg27519622 16 3079877 CCDC64B Body 8,28E-05 
cg00324520 15 41411926 
 
 
9,39E-05 
cg03460109 4 7427313 SORCS2 Body 9,39E-05 
cg06214007 1 89829308 GBP6 TSS200 9,39E-05 
cg06948111 8 64093405 YTHDF3 Body 9,39E-05 
cg06994282 7 2005347 MAD1L1 Body 9,39E-05 
cg12179554 13 114821832 RASA3 Body 9,39E-05 
cg18322822 5 1119648 
 
 
9,39E-05 
cg19113641 2 20866242 GDF7 TSS200 9,39E-05 
cg25004071 20 60639474 TAF4 Body 9,39E-05 
 
  
 Supplemental Figure I: Density plot showing the distribution of normalized methylation 
levels in our data. Bimodal distribution was observed when considering all 451,518 CpG 
sites whereas approximately normal distribution was observed for most individually plotted 
CpG sites. (a) Beta across all CpGs analyzed; (b) Beta for one representative CpG 
(cg03548645). X-axis indicates methylation 
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β-values and Y-axis frequency.
 
 
 
 Supplemental Figure II: Clustering heatmap of the 73 differentially methylated CpG sites 
identified by 450k analysis. The green/red color bar indicates the sample type according 
to case-control classification in Figure 2. Each column represents a sample and each 
horizontal line represents the methylation levels of a given CpG across samples. 
Methylation levels are expressed as 0
completely methylated, respectively).
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-1 β-values (green and red, unmethylated and 
 
 
 
 Supplemental Figure III: Box plot representation of 73 DMCs. 48 CpG sites show higher 
methylation levels in vascular recurrent patients than in non
above the line. 25 CpG sites show lower methylation levels in vascular recurrent patients 
than in non-vascular recurrent patients, below the line.
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-vascular r
 
 
ecurrent patients, 
 
 Supplemental Figure IV: Box plot representing the differences between recurrent and 
non-recurrent patients from each independent cohort of the validation study. 
box plots represent recurrent patients, and grey box plots re
patients.  Y-axe: Methylation levels.
Supplemental Figure V: 
differences between recurrent and non
and non-atherothrombotic patients. White box plots represent recurrent patients, and grey 
box plots represent non-recurrent patients. 
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present non
  
Box plot representing the cg03548645 methylation levels 
-recurrent stroke patients within atherothrombotic 
 
 
X-axe: white 
-recurrent 
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Supplemental Figure VI: Box plot representing the TRAF3 methylation levels differences 
between recurrent and non-recurrent stroke patients treated with aspirin. White box plots 
represent recurrent patients, and grey box plots represent non-recurrent patients.  
 
 
 
